(Q46220793)

20 December 2017

title

Obesity-related cardiometabolic complications (English)

1 reference

20 December 2017

0 references

Christopher P Cannon

1

1 reference

20 December 2017

publication date

1 January 2008

1 reference

20 December 2017

published in

Clinical cornerstone

1 reference

20 December 2017

volume

9

1 reference

20 December 2017

issue

1

1 reference

20 December 2017

page(s)

11-9; discussion 20-2

1 reference

20 December 2017

Prevalence of overweight and obesity in the United States, 1999-2004

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2808%2960024-1

7 January 2021

Obesity and diabetes in the developing world--a growing challenge

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2808%2960024-1

7 January 2021

Excess deaths associated with underweight, overweight, and obesity

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2808%2960024-1

7 January 2021

Overweight, obesity, and mortality in a large prospective cohort of persons 50 to 71 years old.

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2808%2960024-1

7 January 2021

A potential decline in life expectancy in the United States in the 21st century

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2808%2960024-1

7 January 2021

Body mass index, waist circumference, and health risk: evidence in support of current National Institutes of Health guidelines

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2808%2960024-1

7 January 2021

Impact of overweight on the risk of developing common chronic diseases during a 10-year period

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2808%2960024-1

7 January 2021

Cause-specific excess deaths associated with underweight, overweight, and obesity

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2808%2960024-1

7 January 2021

Explaining the Decrease in U.S. Deaths from Coronary Disease, 1980–2000

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2808%2960024-1

7 January 2021

Obesity and the role of adipose tissue in inflammation and metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2808%2960024-1

7 January 2021

The burden of adult hypertension in the United States 1999 to 2000: a rising tide.

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2808%2960024-1

7 January 2021

Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004.

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2808%2960024-1

7 January 2021

Obesity-associated hypertension: new insights into mechanisms.

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2808%2960024-1

7 January 2021

Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2808%2960024-1

7 January 2021

Telmisartan/hydrochlorothiazide versus valsartan/hydrochlorothiazide in obese hypertensive patients with type 2 diabetes: the SMOOTH study

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2808%2960024-1

7 January 2021

Optimal treatment of obesity-related hypertension: the Hypertension-Obesity-Sibutramine (HOS) study

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2808%2960024-1

7 January 2021

Screening for type 2 diabetes mellitus in adults: U.S. Preventive Services Task Force recommendation statement

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2808%2960024-1

7 January 2021

Mechanisms linking obesity to insulin resistance and type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2808%2960024-1

7 January 2021

Adiponectin, insulin resistance and clinical expression of the metabolic syndrome in patients with Type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2808%2960024-1

7 January 2021

Effect of insulin resistance, dyslipidemia, and intra-abdominal adiposity on the development of cardiovascular disease and diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2808%2960024-1

7 January 2021

Standards of medical care in diabetes--2008.

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2808%2960024-1

7 January 2021

Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2808%2960024-1

7 January 2021

Bodyweight changes associated with antihyperglycaemic agents in type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2808%2960024-1

7 January 2021

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2808%2960024-1

7 January 2021

Pathophysiological significance of adiponectin

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2808%2960024-1

7 January 2021

Effects of Obesity on Lipid-Lowering, Anti-Inflammatory, and Antiatherosclerotic Benefits of Atorvastatin or Pravastatin in Patients With Coronary Artery Disease (from the REVERSAL Study)

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2808%2960024-1

7 January 2021

Risk of cardiovascular and all-cause mortality in individuals with diabetes mellitus, impaired fasting glucose, and impaired glucose tolerance: the Australian Diabetes, Obesity, and Lifestyle Study (AusDiab)

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2808%2960024-1

7 January 2021

Reverse causality and confounding and the associations of overweight and obesity with mortality

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2808%2960024-1

7 January 2021

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2808%2960024-1

7 January 2021

Weight loss with a low-carbohydrate, Mediterranean, or low-fat diet

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2808%2960024-1

7 January 2021

Physical activity and public health: updated recommendation for adults from the American College of Sports Medicine and the American Heart Association.

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2808%2960024-1

7 January 2021

Physical Activity and Public Health in Older Adults

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2808%2960024-1

7 January 2021

Suboptimal control of glycemia, blood pressure, and LDL cholesterol in overweight adults with diabetes: the Look AHEAD Study

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2808%2960024-1

7 January 2021

The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2808%2960024-1

7 January 2021

Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2808%2960024-1

7 January 2021

Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2808%2960024-1

7 January 2021

Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2808%2960024-1

7 January 2021

Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2808%2960024-1

7 January 2021

10.1016/S1098-3597(08)60024-1

Identifiers

DOI

1 reference

20 December 2017

PubMed ID

19046736

1 reference

20 December 2017